Latest Ivacaftor Stories
Prime Therapeutics study finds combination treatment targeting gene mutations could add approximately $150 million per year in new costs ST.
DALLAS, March 12, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Cystic Fibrosis - Pipeline Review, H1 2015" therapeutic market research report provides an overview of
Global Cystic Fibrosis Market 2015-2019 is a new industry research report which profiles key players like Actavis, Novartis, Gilead Sciences, Vertex Pharmaceuticals and F Hoffmann-La Roche.
Largest pharmaceutical royalty purchase ever completed NEW YORK, Nov.
Editor Note: For more information about this release, please scroll to bottom. NEW YORK, October 27, 2014 /PRNewswire/ -- Today, Analysts Review released its research
HAMILTON, N.J., Oct.
ChanTest’s expertise will be showcased at the North American Cystic Fibrosis Conference this month, highlighting the important research the company has conducted to help move cystic fibrosis
Expanded Collaboration Supports Phase 2 Clinical Trial Initiation of First-In-Class ENaC Inhibitor for the Treatment of Cystic Fibrosis DURHAM, N.C., Sept.
Cystic fibrosis continues to be devastating for many people around the world.
SAN FRANCISCO, Aug.
- A woman chauffeur.
- A woman who operates an automobile.